Efficient Expression of Functionally Active Aflibercept with Designed N-glycans.

Fc fusion aflibercept anti VEGF glycan engineering glycosylation plant expression

Journal

Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489

Informations de publication

Date de publication:
07 Apr 2024
Historique:
received: 14 12 2023
revised: 05 03 2024
accepted: 27 03 2024
medline: 23 4 2024
pubmed: 23 4 2024
entrez: 23 4 2024
Statut: epublish

Résumé

Aflibercept is a therapeutic recombinant fusion protein comprising extracellular domains of human vascular endothelial growth factor receptors (VEGFRs) and IgG1-Fc. It is a highly glycosylated protein with five N-glycosylation sites that might impact it structurally and/or functionally. Aflibercept is produced in mammalian cells and exhibits large glycan heterogeneity, which hampers glycan-associated investigations. Here, we report the expression of aflibercept in a plant-based system with targeted N-glycosylation profiles.

Identifiants

pubmed: 38651409
pii: antib13020029
doi: 10.3390/antib13020029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FWF Austrian Science Fund
ID : I 4328-B
Organisme : FWF Austrian Science Fund
ID : I 3721-B30
Organisme : Austrian Research Promotion Agency
ID : COMET-Competence Centers for Excellent Technologies

Auteurs

Tahereh Keshvari (T)

Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.
Institute of Biotechnology, Shiraz University, Shiraz 71441-65186, Iran.

Stanislav Melnik (S)

Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.

Lin Sun (L)

Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.

Ali Niazi (A)

Institute of Biotechnology, Shiraz University, Shiraz 71441-65186, Iran.

Farzaneh Aram (F)

Institute of Biotechnology, Shiraz University, Shiraz 71441-65186, Iran.

Ali Moghadam (A)

Institute of Biotechnology, Shiraz University, Shiraz 71441-65186, Iran.

Benjamin Kogelmann (B)

Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.
ACIB-Austrian Centre of Industrial Biotechnology, 1190 Vienna, Austria.

Gordana Wozniak-Knopp (G)

Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.

Somanath Kallolimath (S)

Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.

Amin Ramezani (A)

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.

Herta Steinkellner (H)

Institute of Plant Biotechnology and Cell Biology, Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences BOKU Vienna, 1190 Vienna, Austria.

Classifications MeSH